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Abstract
Introduction: The results of many studies have reported that peptides from the angiotensin family are involved in the regulation of cell
growth, proliferation, cell migration, apoptosis, inflammation, differentiation, and angiogenesis, which suggests that they might play an
important role in carcinogenesis. The role of the renin–angiotensin system in supporting prostate cancer induction and progression has so
far received little study.
Material and methods: The present study was to examine the influence of Ang II, Ang III, and Ang IV on a human hormone-dependent
prostate cancer line (LNCaP). Using an isotopic method, we tested the effects of angiotensins on tyrosine kinase activity, and measured
cell viability using an MTT Assay.
Results: The results showed that only Ang IV significantly reduced tyrosine kinase activity and cell viability in LNCaP cells. The process
seemed to be mediated partly by AT2 and probably by another type of receptor with high affinity for Ang IV and low affinity for PD123319
and Losartan.
Conclusions: These findings suggest that components of the renin-angiotensin system, specifically angiotensin peptides and receptors
(AT1, AT2) can modify prostate cancer cell viability. (Pol J Endocrinol 2009; 60 (5): 363–369)
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Streszczenie
Wstęp: Wyniki wielu badań wskazują, że peptydy z rodziny angiotensyn są włączone w regulację cyklu komórkowego, apoptozę, różni-
cowanie się komórek, jak również odgrywają istotną rolę w procesach zapalnych i migracji komórek. Ich zaangażowanie w tak istotne
procesy sugeruje, że mogą one odgrywać istotną rolę w procesie kancerogenezy. Stosunkowo mało wiadomo na temat roli systemu
renina–angiotensyna w zapoczątkowaniu i późniejszym rozwoju raka stercza.
Materiał i metody: Poniższe wyniki przedstawiają wpływ Ang II, Ang III, Ang IV na linię komórkową ludzkiego hormonozależnego raka
prostaty. Używając metody izotopowej, badano wpływ wybranych angiotensyn na aktywność kinaz tyrozynowych. Podczas gdy przeży-
walność komórkowa była oznaczana za pomocą testu MTT.
Wyniki: Wyniki wskazują, że tylko Ang IV w sposób istotny statystycznie redukuje aktywność kinaz tyrozynowych i obniża przeżywal-
ność komórek linii LNCaP. Proces ten był pośredniczony przez receptor AT2 i prawdopodobnie przez inny receptor, o wysokim powino-
wactwie dla Ang IV i niskim dla PD123319 i losartanu.
Wnioski: Otrzymane wyniki sugerują, że komponenty układu renina–angiotensyna, w tym szczególnie peptydy angiotensynowe oraz
klasyczne receptory dla angiotensyn (AT1, AT2), mogą modyfikować przeżywalność komórek raka gruczołu krokowego.
(Endokrynol Pol 2009; 60 (5): 363–369)
Słowa kluczowe: hormonozależny rak gruczołu krokowego, LNCaP, przeżywalność komórkowa, PTKs, losartan, PD123319
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Prostate cancer is the most commonly diagnosed inva-
sive cancer in men. In 2007, an estimated 218,890 men
were diagnosed with prostate cancer, and there were
an estimated 27,050 deaths due to prostate cancer [1].
During the last decade, it has been established that the
renin-angiotensin-aldosterone system (RAAS) is not
only concerned with cardiovascular system and water-
electrolyte balance. Angiotensin II (Ang II) can be local-
ly produced and selectively regulated in many tissues
and organs, for instance the adrenal, kidney, brain, bre-
ast, and prostate [2–4]. The expression of components
of the local RAS, such as ACE and membrane receptors
AT1 and AT2, has been found in human and rat prostate
cells [5].
The first and most active multifunctional hormone
of the renin-angiotensin-aldosterone system is angio-
tensin II. The existence of RAS in the prostate gland
strongly supports the finding that human seminal pla-
sma contains Ang II in concentrations from 3- to 5-fold
higher than in circulating blood plasma. Therefore, it is
appropriate to determine the source of this secreted
angiotensin II [6]. The results of many studies have re-
ported that Ang II is involved in the regulation of cell
growth, proliferation, cell migration, apoptosis, inflam-
mation, differentiation, and angiogenesis, which indi-
cates a possible important role in cancer [7–9]. These
various effects are often the consequence of Ang II-in-
duced activation of many cytoplasmic tyrosine kinases
and transactivation of membrane associated growth
factor receptor kinases [10–12].
In mammalian cells, Ang II mediates biological ef-
fects through binding to two classical angiotensin re-
ceptors. Interestingly, Ang II induces cell proliferation
by activating AT1-receptors, but stimulation of the AT2-
receptor inhibits cell growth in different cell types [13–
–15]. Analyses have shown that the AT1 mRNA level is
significantly higher in prostate cancer tissue than in
control normal prostate tissue [12].
The octapeptide Ang II is converted into the vario-
us shorter, active angiotensin fragments by aminopep-
tidases (Fig. 1). These other RA system peptides also
possess important functions. The physiological actions
of the bioactive angiotensin peptides depend on their
chemical structure and their specificity for the receptors,
the information transducers at the cellular level [16].
The aims of this study were to compare the effects
of different concentrations of angiotensin peptides (Ang
II, Ang III, Ang IV) on protein tyrosine kinases (PTKs)
activity and viability of cells of the prostate cancer cell
line, LNCaP.
Moreover, we examined the potential association of
the effects of Ang II, III, IV with two types of angioten-
sin receptor using selective antagonists of AT1 (Losar-
tan) and AT2 (PD 123319).
Material and methods
Cell Line
LNCaP cells were cultured in RPMI 1640 medium that
was supplemented with 10% heat-inactivated Foetal
Bovine Serum (FBS), 2 mM L-glutamine, 1 mM Sodium
Pyruvate, 10 mM Hepes Buffer, and antibiotics (Peni-
cillin 50 U/ml; Streptomycin 50 µg/ml; Neomycin
100 µg/ml) at 37°C in a humidified atmosphere of 5% CO2
in air. These cell cultures were passaged once a week
Reagents
Angiotensins II, III and IV were purchased from Ba-
chem. Adamed donated a selective AT1 antagonist (Lo-
sartan). The nonpeptide AT2 antagonist, PD 123319, was
from Sigma.
Phosphorylation Assay for PTK Activity
A modification of Hirano’s method for the determina-
tion of protein kinase activity was used. The most im-
portant advantage of this method is its high sensitivity.
Five-day-old LNCaP cultures were preincubated for
15 min at 37°C with angiotensin peptides (Ang II, Ang
III, Ang IV) at the following concentrations: 0.05 nM,
Figure 1. Cascade of enzymatic reactions of the renin–angiotensin
system (RAS) leading to the formation of Ang II, Ang III, and
Ang IV; ACE — angiotensin converting enzyme; APA —
aminopeptidase A; APN — aminopeptidase N; APB —
aminopeptidase B; DAP — dipeptidyl aminopeptidase
Rycina 1. Kaskada enzymatyczna układu renina–angiotensyna
prowadząca do powstania Ang II, Ang III i Ang IV; ACE — enzym
konwertujący angiotensynę; APA — aminopeptidasa A; APN —
aminopeptidasa N; APB — aminopeptydaza B; DAP — dipeptidyl
aminopeptidase
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0.5 nM, 5 nM. Combinations of angiotensins and 50 nM
Losartan (specific AT1 antagonist) or 50 nM PD123319
(specific AT2 antagonist) were also tested.
Then the cells and drugs were incubated with 0.1%
TRITON-X-100 for 15 min at 0°C. The standard pho-
sphorylation assay medium contained: 20 mM TRIS/HCl
pH-7.4, 20 mM MgCl2, 2 mM MnCl2, 1 mM EGTA,
0.5 mM EDTA, 0.1 M DTT, 1 mM ouabain and 1 mM
Na2VO4  as phosphatase inhibitors and 200 µM g
32P-ATP
as a phosphate donor in the phosphorylation reaction.
The reaction was started by adding treated cells to pho-
sphorylation assay medium in the presence or absence
(control group) of 200 µg/ml polyGlu, Tyr (4:1) as the
substrate. After incubation in a water bath at 30°C for
7 min, the reaction was stopped by the addition of 20 µl
of a mixture of 5 mM ATP and 0.25 mM EDTA. A 50 µl
aliquot of reaction mixture was then spotted onto
a Whatman paper disc. The discs were washed three
times in cold 10% TCA with 5% sodium pyrophospha-
te. The 32P radioactivity was counted via Cerenlcov ra-
diation. The specific activities of PTKs were defined as
pmoles of radioactive 32P incorporation per mg of exo-
genous polyGlu,Tyr per min. The results were compa-
red to basal activity of protein tyrosine kinase obtained
from samples not containing any tested compounds
(basal activity assumed to be 100%).
MTT Assay for Cell Viability
The principle of this assay is that MTT (3-(4,5-dimethyl-
thiazol-2-yl)-2,5-diphenyl tetrazolium bromide) is redu-
ced by the mitochondrial dehydrogenase of viable cells
into dark blue formazan crystals that can be measured
spectrophotometrically. The number of surviving cells
is directly proportional to the level of the formazan pro-
duct created.
For cell viability studies, LNCaP cells were plated at
a density of 2 × 103 cells/well in 96-well plates and were
maintained overnight in complete medium.
Briefly, LNCaP cells cultured in 96-well plates were
incubated (24 h) with 5000 nM – 0.005 nM angiotensin
peptides (Ang II, Ang III or Ang IV) in the presence and
absence of 5000 nM Losartan or 5000 nM PD123319. The
control cells were grown under the same conditions,
without the addition of the compounds. After incuba-
tion, the medium was discarded and 100 µl of MTT
(0.5 mg/ml PBS) was added to each well. The cells were
then incubated at 37°C, in 5% CO2 for 2–3 hours. The
MTT solution was removed from the wells by aspiration,
and the formazan crystals were dissolved in 50–80 µl of
DMSO. Plates were shaken for 2 minutes and absor-
bance was recorded at 620 nm. Cell survival (% of con-
trol) was calculated relative to untreated control cells.
Statistical evaluation
All data are expressed as mean ± SEM. Statistical signi-
ficance was assessed by analysis of variance (On-Way
ANOVA) for repeated measurements followed by the
LSD post-hoc test to determine the extent of the diffe-
rences using the StatGraphics Plus 6.0. A significance
level of 5% was chosen (p < 0.05).
Results
PTKs activity
The exposure of LNCaP cells to Ang IV decreased PTK
activity (Fig. 2). The activity of tyrosine kinases was si-
gnificantly lower than in controls, amounting to 73.3%,
74% and 73.7% of the control value for respective con-
centrations: 0.05 nM, 0.5 nM, and 5 nM. In contrast, Ang
II was ineffective at all tested concentrations. The effect
of Ang III on kinase activity depended on concentra-
tion. This peptide slightly inhibited the tested enzyme
at a concentration 0.05 nM whereas higher concentra-
tions were ineffective.
Losartan alone (AT1 antagonist) was ineffective on
Ang IV-induced changes in PTK activity (Fig. 3). In con-
trast, when Losartan was added together with Ang IV,
the degree of phosphorylation was lower (0.05 nM) or
similar (0.5 nM, 5 nM) to the effect of Ang IV alone (Fig. 3).
PD123319 (AT2 antagonist) alone slightly decreased PTK
activity. The combination of PD123319 and Ang IV par-
tly reversed the inhibitory effect of Ang IV at concen-
trations of 0.05 nM and 0.5 nM but not 5 nM (Fig. 4).
Figure 2. The influence of Ang II, III, IV on PTK activity in
LNCaP cells. X ± SEM; *p < 0.05, **p < 0.01 v. C
Rycina 2. Wpływ Ang II, III i IV na aktywność PTK w komórkach
LNCaP. X ± SEM; *p < 0,05, **p < 0,01 v. C
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To assess the reduced enzyme activity of the cells, we
used the MTT assay to evaluate the effect of angiotensin
peptides on viability. Human androgen-dependent
LNCaP cells were treated for 24 hours with various con-
centrations of Ang II, Ang III, and Ang IV (5000–0.005 nM).
The incubation of LNCaP cells with Ang IV resulted
in a significant decrease in cell viability, at all tested con-
centrations (Fig. 5). The maximum suppression of via-
bility relative to control cells was observed at concen-
trations of 5 nM and 5000 nM Ang IV, which reduced
viability to 76%. The effect of Ang II and Ang III on cell
viability was generally similar to the control, with no
statistically significant effect on viability observed, at any
concentration.
Exposure of LNCaP cells to Losartan alone (AT1
antagonist; 5000 nM) and together with Ang IV resul-
ted in similar effects on cell growth (Fig. 6). PD 123319
(AT2 antagonist) alone decreased cell survival to 82%
of the control value. The AT2 receptor inhibitor given
together with Ang IV promoted survival of LNCaP cells
in comparison with treatment with Ang IV alone or PD
123319 alone (Fig. 7).
Discussion
The LNCaP cell line is one of the few lines that have
been most commonly used for the majority of publi-
shed research on prostate cancer. This line was isolated
Figure 3. The influence of Losartan on Ang IV-induced effect on
PTK activity in LNCaP cells. X ± SEM; * p < 0.05, ** p < 0.01
Rycina 3. Wpływ losartanu na oddziaływanie Ang IV na aktywność
PTK w komórkach LNCaP. X ± SEM; * p < 0,05, ** p < 0,01
Figure 4. The influence of PD123319 on Ang IV-induced effect
on PTK activity in LNCaP cells. X ± SEM; * p < 0.05, ** p < 0.01
Rycina 4. Wpływ PD123319 na oddziaływanie Ang IV na aktywność
PTK w komórkach LNCaP. X ± SEM; * p < 0,05, ** p < 0,01
Figure 5. Effect of angiotensin peptides (Ang II, III, IV) on cell
viability of prostate cancer cells LNCaP. X ± SEM
Rycina 5. Wpływ peptydów z rodziny angiotensyn (Ang II, III,
IV) na żywotność komórek raka prostaty z linii LNCaP. X ± SEM
Figure 6. The influence of Losartan on Ang IV-induced effect on
cell viability of prostate cancer cells LNCaP. X ± SEM
Rycina 6. Wpływ losartanu na oddziaływanie Ang IV na
przeżywalność komórek raka prostaty z linii LNCaP. X ± SEM
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in 1977 from the left supraclavicular lymph node of
a 50-year-old Caucasian male with confirmed diagno-
sis of metastatic prostate adenocarcinoma [17]. Since the
androgen-dependent LNCaP cells are slow growing
and not aggressively tumorigenic, we used them as
a model of early stage prostate cancer. The potential
role of the renin-angiotensin system in induction and
progression of prostate cancer has been uncovered re-
cently.  We have strong evidence that a local RAS exists
in normal and cancer prostate tissue including prostate
cancer cell lines [5, 12]. We also know that same patho-
logical processes, such as inflammation or carcinoge-
nesis, involve changes in particular elements of the RA
System [9, 12, 18, 19].
Ang II may transmit signals through tyrosine kinase
domains in both normal and cancer cells [10–12]. Pre-
vious studies show that Ang II and Ang IV can modula-
te PTK activity in pituitary tumour cells [20]. Therefore,
we decided to evaluate the effects of angiotensin pepti-
des on PTK activity in the LNCaP cell line. The protein
tyrosine kinases are a large family, which catalyze pho-
sphorylation of specific tyrosine residues in target pro-
teins, using ATP. These enzymes play significant roles
in the development of many disease states, including
cancer [21]. Furthermore, tyrosine kinase inhibitors have
recently been reported as novel anticancer drugs [22].
Using an isotopic method (Hirano) we tested three
concentrations of angiotensin peptides on PTK activity
in LNCaP cells. In this study, we focused on rapid ef-
fects of Ang II, III, and IV, evident after a few minutes
of treatment (7 min). The data revealed that only Ang
IV inhibits tyrosine kinase activity at all tested concen-
trations. Earlier studies demonstrated that Ang IV sti-
mulates PTK activity in pituitary tumour cells, but in
normal pituitary tissue this effect was dependent on
concentration [20, 23]. The Hirano technique provides
global information on the level of activation of a large
pool of non-receptor tyrosine kinases, for example Jak,
Fak, Pyk2, and Abl. Because transcription changes usu-
ally take hours, our results indicate that angiotensins
have non-genomic actions on PTK activity.
The tissue actions of angiotensins are mediated via
interaction with at least two specific membrane recep-
tor subtypes: AT1 and AT2. These classic angiotensin
receptors belong to the superfamily of G-protein-co-
upled receptors. It is well-established that GPCRs and
tyrosine kinases can cross-talk and modulate each other
[24]. Here, experiments with specific inhibitors were
performed to investigate the influence of Losartan (AT1
inhibitor) and PD123319 (AT2 inhibitor) on Ang IV-in-
duced effects on PTK activity. In this study, we obse-
rved that AT2 receptor blocker PD123319 partly aboli-
shed the suppressive effect of Ang IV on PTK activity,
but this effect was observed only for lower concentra-
tions of Ang IV (0.05 nM and 0.5 nM). In contrast, a com-
bination of Losartan with the lowest concentration of
Ang IV increased the Ang IV-induced inhibitory effect.
This observation suggests that Ang IV effects on PTK
activity did not occur via AT1 receptor.
Because cell-to-cell signals regarding growth, diffe-
rentiation, adhesion, and cell death are frequently trans-
mitted by tyrosine kinases, we hypothesized that an-
giotensins (especially Ang IV) might influence cell pro-
liferation. Ławnicka et al. reported that Ang II, as well
as its smaller fragments, could decrease the growth of
human hormone-independent prostate cancer cells
(DU-145) in vitro [25]. Using a colourimetric method
(MTT assay), we tested the effect of seven concentra-
tions of angiotensin peptides on viability of LNCaP cells
(Fig. 5). As we hypothesized, Ang IV inhibited not only
the enzyme activity tested but also the viability of
LNCaP cells. The molecular mechanism by which the
angiotensin IV lowered the survival of these hormone-
dependent prostate cancer cells remains unclear. It se-
ems that PTKs could play an important role in suppor-
ting this process because the inhibitory effects of Ang
IV on cell viability paralleled the reduced PTK activity
by Ang IV in LNCaP cells. The next question is regar-
ding the type of angiotensin receptor involved in Ang
IV effects on prostate cancer cell viability. Ang IV inte-
racts with AT1 and AT2 receptors, but only with low af-
finity [26]. Unexpectedly, both Losartan and PD123319
did not significantly block the inhibitory effect of Ang
IV, so it seems that Ang IV effects did not occur via clas-
sic angiotensin receptors. However, the AT2 receptor
antagonist PD 123319 reduced the inhibitory effect of
Ang IV, but it also reduced cell viability when added
alone.  Hence, it is possible to speculate that the inhibi-
tory effect of Ang IV on cell viability is exerted partly
via AT2 but probably also via another subtype of angio-
Figure 7. The influence of PD123319 on Ang IV-induced effect
on cell viability of prostate cancer cells LNCaP. X ± SEM
Rycina 7. Wpływ PD123319 na oddziaływanie Ang IV na
żywotność komórek raka prostaty z linii LNCaP. X ± SEM
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tensin receptor, exhibiting high sensitivity to Ang IV.
Recent evidence has suggested that the high affinity
binding sites for this peptide (AT4 receptor) may be the
insulin-regulated aminopeptidase (IRAP). The AT4 bin-
ding site has been found in a variety of mammalian tis-
sues including heart vascular smooth muscle, kidney,
colon, adrenal gland, brain, and prostate. The role of
the AT4 receptor is poorly understood but it has been
suggested that it may regulate blood flow, memory re-
tention, and neuronal development [26, 27].
Pawlikowski et al. tested proliferation of prostatic
epithelium cells after treatment with Ang II and Ang IV.
This group of authors has also reported that angioten-
sins are involved in the control of prostate cell growth,
acting via receptors different from AT1. However, they
observed a stimulatory effect of angiotensins on pro-
state cell proliferation. These findings suggest that bio-
logical properties of peptides from the angiotensin fa-
mily can be different in physiological and pathological
prostate tissue [28].
In the present study, we also focused on the biolo-
gical role of Ang II and Ang III on cell viability in pro-
state cancer cells. Similar to actions on PTK activity, we
did not observe significant changes in cell growth after
treatment with these peptides.
Conversely, several recent reports indicate that Ang
II and Ang III stimulate proliferation of prostate cells
via AT1 [12, 29–31]. It is possible to explain the lack of
effect of Ang II in our study as follows. Firstly, MTT
reduction in a homogenous sample of cells like the
LNCaP cell line is frequently used as an indicator of cell
proliferation; however, MTT reduction is proportional
to the number of metabolically active cells. Therefore,
in interpreting our results obtained with MTT assay we
draw conclusions regarding the effects on viability ra-
ther than proliferation, because the method is based on
mitochondrial function and not on DNA synthesis. Se-
condly, the time of incubation of LNCaP cells with Ang II
was shorter than in other published studies. Uemura et al.
cultured LNCaP cells in the presence of Ang II for
5 days [12], and Chow et al. for 3 days [29], whereas the
incubation time in our study was only 24 hours. Alter-
natively, our results obtained with LNCaP cells, after
treatment with Ang II and Ang III, are consistent with
results for humane lung cancer cells. Gallagher and
Menon et al. showed that both Ang II and Ang III did
not significantly affect cell proliferation in SK-LU-1 cells
when treated for 24 hours [32].
Conclusions
In summary, these experimental results demonstra-
te that only Ang IV significantly reduced cell viability
in a human hormone-dependent prostate cancer cell
line after a 24-hour incubation period. Unexpectedly,
both of the longer peptides (Ang II and Ang III) were
ineffective. Moreover, our observations suggested that
Ang IV effects did not occur via AT1. The process seems
to be mediated partly by AT2 and probably by another
type receptor with high affinity for Ang IV and low af-
finity for PD123319 and Losartan. At this point, we can
only speculate about the mechanism by which Ang IV
inhibits cell viability in LNCaP cells. However, it is po-
ssible that the tyrosine kinases are involved in the early
signalling pathway of this process. Future investigations
are necessary to extend these results.
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